Principal Financial Group
TCRT icon

Principal Financial Group’s Alaunos Therapeutics TCRT Stock Holding History

Principal Financial Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-418
Closed -$41K – 2640
2022
Q1 		$41K Buy
418
+8
+2% +$1.03K ﹤0.01% 2496
2021
Q4 		$67K Sell
410
-177
-30% -$38.9K ﹤0.01% 2467
2021
Q3 		$160K Buy
587
+34
+6% +$10.4K ﹤0.01% 2458
2021
Q2 		$219K Sell
553
-19
-3% -$8.87K ﹤0.01% 2448
2021
Q1 		$309K Buy
572
+6
+1% +$3.73K ﹤0.01% 2268
2020
Q4 		$213K Buy
566
+136
+32% +$54.1K ﹤0.01% 2309
2020
Q3 		$163K Sell
430
-39
-8% -$17.2K ﹤0.01% 2232
2020
Q2 		$231K Buy
469
+134
+40% +$59.7K ﹤0.01% 2148
2020
Q1 		$123K Buy
335
+23
+7% +$11.9K ﹤0.01% 2106
2019
Q4 		$221K Buy
312
+18
+6% +$12.4K ﹤0.01% 2116
2019
Q3 		$189K Buy
294
+25
+9% +$19.8K ﹤0.01% 2150
2019
Q2 		$235K Buy
269
+20
+8% +$13.8K ﹤0.01% 2117
2019
Q1 		$144K Sell
249
-1
-0.4% -$418 ﹤0.01% 2143
2018
Q4 		$70K Sell
250
-47
-16% -$18.6K ﹤0.01% 2186
2018
Q3 		$143K Buy
297
+37
+14% +$15.9K ﹤0.01% 2204
2018
Q2 		$117K Sell
260
-19
-7% -$12K ﹤0.01% 2213
2018
Q1 		$164K Sell
279
-1
-0.4% -$623 ﹤0.01% 2125
2017
Q4 		$173K Buy
280
+144
+106% +$103K ﹤0.01% 2150
2017
Q3 		$125K Sell
136
-24
-15% -$21.3K ﹤0.01% 2131
2017
Q2 		$150K Buy
160
+11
+7% +$10.8K ﹤0.01% 2157
2017
Q1 		$142K Hold
149
– – ﹤0.01% 2121
2016
Q4 		$120K Buy
149
+4
+3% +$3.6K ﹤0.01% 2141
2016
Q3 		$123K Buy
145
+2
+1% +$1.61K ﹤0.01% 2088
2016
Q2 		$117K Buy
143
+8
+6% +$8.71K ﹤0.01% 2074
2016
Q1 		$150K Buy
135
+3
+2% +$3.07K ﹤0.01% 2053
2015
Q4 		$165K Buy
132
+3
+2% +$4.96K ﹤0.01% 2072
2015
Q3 		$175K Buy
129
+14
+12% +$23.1K ﹤0.01% 2050
2015
Q2 		$208K Buy
115
+28
+32% +$43.5K ﹤0.01% 2035
2015
Q1 		$141K Buy
+87
New +$129K ﹤0.01% 2066
2014
Q3 		– Sell
-184
Closed -$111K – 2236
2014
Q2 		$111K Buy
+184
New +$102K ﹤0.01% 2194

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Principal Financial Group's TCRT Position: Q2 2022 in Review

Principal Financial Group sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 418 shares — an estimated $41K sold.

Principal Financial Group first reported a position in TCRT in Q2 2014 and held it in 30 quarters. The position peaked at $309K in Q1 2021. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Principal Financial Group reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Principal Financial Group sold 418 Alaunos Therapeutics shares in Q2 2022, an estimated $41K.
  • Principal Financial Group first reported a position in Alaunos Therapeutics in Q2 2014 and held it in 30 quarters.
  • Principal Financial Group's Alaunos Therapeutics position peaked at $309K in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Principal Financial Group's 13F filing for Q2 2022, filed 10 Aug 2022.